Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVS-3001 in Advanced HLA-G-Positive Solid Tumors
NCT05672459Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2023
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous anti-HLA-G CAR-T cells IVS-3001 in solid tumor, clear cell renal cell carcinoma (ccRCC) and epithelial ovarian carcinoma (EOC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of Adverse Events at 3 years and Objective Response Rate at 3 years. Started Jun 2023; status: active, not recruiting.
02
Drugs
autologous anti-HLA-G CAR-T cells IVS-3001
03
Conditions
solid tumorclear cell renal cell carcinoma (ccRCC)epithelial ovarian carcinoma (EOC)
Beyond the preview
Go deeper on NCT05672459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672459.